What is CAR-T Cell Therapy?
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary form of immunotherapy that uses the body's own immune system to fight cancer. The process involves:
- Extraction: T-cells (a type of white blood cell) are extracted from the patient's blood
- Genetic Engineering: In a laboratory, these T-cells are genetically modified to produce special receptors called Chimeric Antigen Receptors (CARs)
- Multiplication & Infusion: These modified "supercharged" T-cells are multiplied by the millions and infused back into the patient's bloodstream
- Action: The CARs act like heat-seeking missiles, enabling T-cells to specifically recognize, bind to, and destroy cancer cells bearing a specific antigen (protein)
Breakthrough Findings for Solid Tumors
Limitations of Conventional CAR-T Therapy
- Conventional CAR-T therapy has been highly successful against blood cancers (leukemia, lymphoma) but struggles in solid tumors
- It requires strong antigen signals for activation
- Due to antigen heterogeneity (variation in surface antigens among cells), many tumor cells express very low levels of target proteins, allowing them to evade immune attack
Key Discovery: Pseudo-Heterogeneity
- Scientists discovered that tumor cells are not truly antigen-negative but express target proteins at very low levels - this is called pseudo-heterogeneity
- Cancer cells likely retain small amounts of proteins because they are necessary for survival
- The enzyme EZH2 suppresses CD70 expression by modifying chromatin structure
- CD70 protein is found in 70-80% of kidney and ovarian cancers, and about 25% of pancreatic cancers
- Research found that 80-90% of tumor cells previously labeled CD70-negative still carry detectable levels
The Solution: HIT Receptor
- Scientists developed the HLA-independent T-cell (HIT) receptor
- This directly links antigen detection to the T-cell's natural activation pathway
- Allows T-cells to respond to much lower antigen densities
- In xenograft models (human tumors grown in mice), conventional CAR-T failed while HIT T-cells achieved complete, lasting tumor removal
- Safety concerns: Higher sensitivity may attack normal cells, but CD70 is mostly absent in vital organs
Major Risks and Limitations
| Risk | Description |
|---|---|
| Cytokine Release Syndrome (CRS) | Severe, potentially life-threatening side effect where activated T-cells release massive inflammatory cytokines, causing high fever, blood pressure drops, and organ dysfunction |
| Neurotoxicity (ICANS) | Neurological issues like confusion, delirium, or seizures |
| High Cost | Globally costs hundreds of thousands of dollars (customized for each patient) |
| Manufacturing Time | Process takes several weeks, during which aggressive cancers can progress |
India's Progress: NexCAR19
NexCAR19 - India's first indigenously developed CAR-T cell therapy - approved in October 2023.
- Developed by: ImmunoACT, IIT Bombay, and Tata Memorial Hospital
- Purpose: Treat B-cell lymphomas and B-acute lymphoblastic leukemia
- Significance: Brought down cost from approximately Rs 3-4 crores (imported) to around Rs 40 lakhs, democratizing access to cutting-edge cancer care in India
Constitutional and Policy Context
- The approval of NexCAR19 aligns with India's Atmanirbhar Bharat initiative for self-reliance in advanced healthcare technologies
- The National Health Policy emphasizes accessibility and affordability of advanced medical treatments
- CDSCO (Central Drugs Standard Control Organisation) approved this therapy for clinical use
UPSC Relevance
This topic is relevant for:
- Science & Technology: Understanding immunotherapy, genetic engineering, and Biotechnology
- Health: Cancer treatment innovations, healthcare accessibility
- Governance: Drug approval processes, healthcare policy
- Economy: Cost reduction in medical treatments, indigenous innovation